GlaxoSmithKline declares Rs7 dividend

According to Mettis Global, GlaxoSmithKline Pakistan Limited, listed on the PSX as GLAXO, lifted net profit 9% to Rs4.58bn in the six months to June 30, 2026. That is up from Rs4.20bn in the same period last year. Along with these results, the company declared an interim cash payout of Rs7 per share.

Net revenue rose 4% to Rs31.52bn from Rs30.30bn, while cost of sales was almost unchanged at Rs19.60bn, lifting gross profit 11% to Rs11.92bn. Earnings per share rose to Rs14.38 from Rs13.17 for the period. Operating profit increased 10% to Rs7.96bn even though administrative expenses jumped 24% to Rs1.26bn.

Finance charges fell 86% to Rs29.53m from Rs214.42m, lifting profit before tax 13% to Rs7.93bn. Income tax expense rose 19% to Rs3.35bn from Rs2.82bn. Other operating expenses rose 10% to Rs676.84m, while other income slipped 4% to Rs713.17m.